NIFEDPINE TABALETS

RETARD 1 mg

COMPOSITION :  Each sustained release film coated tablet         containns:
                                  Nifedipine S.S.P 10g

DESCRIPTION :  

 Calcium Antagonist, Cardiovascular therapeutic agent ( Antihypetensive & Antianginal)

PHARMACOLOGY :

Absorption :

Absorption is nearly complete from the jejunum after oral administration. Biovailability is however variable depending on first pass hepatic metabolism and ranges from 43 to 77% food increase the biovalibility of sustained release nifedipine tablet, tmax is attained at 6.0 hours. Nifedipine is highly bound to plasma proteins (92 to 98%) in particular albumin.

ELIMINATION :

The eliminate half-life of sustained release nifedpine is 10.5 hours. No accumulation of unchaned active substance is to be expected in the case of long term medication. Nifedpine is almost totally metabolized and only traces thereof are found in unchanged form of inactive metabolites and the rest in excreted in the faeces.

CLINICAL SITUATION WITH POSSIBLY CHANGED KINETICS :

In the case of renal insufficiency the kinetics are not affected although the hypotensive effect is enchanced. Doses of nifedipine must be reduced in liver cirrhosis.

MECHANISM OF ACTION :

Nifedipine inhibits the influx of calcium into  the heart muscle cells, the smooth muscle cell of the coronary arteries and the perpheral  arterioles (resistance vessels) nifedipine brings about an improvement in the oxygen supply to the heart muscle with simultaneous reduction of oxygen requirements, thereby exerting an antianginal effect. Normalization of eveated blood pressure is brough about by a reduction in peripheral resistance though the dilatation of the arterioles.

USUAL DOSAGE :

1 tablet of nicardia retard twice daily.

CONTRAINDICATIONS :

Nicardia retard to be avoide during pregnancy. No data are available regarding use in lacation. Nicardia retard should not be used in severe hypotension with danger of collapse.

SIDE EFFECTS :

The most common adverse effects of nifedipine therapy are headache flushing, dizziness, gastrointestinal symptoms and lower leg oedema, sweelling or fluid retention.
The main vasodilator related adverse of nifedipine is headache – flushing and dizziness have reported to necessitate treatment withdrawal in 2 to 6% of patients.